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Abstract
The abnormal accumulation of fat in the liver is often related either to metabolic risk factors associated with metabolic
syndrome in the absence of alcohol consumption (nonalcoholic fatty liver disease, NAFLD) or to chronic alcohol
consumption (alcoholic fatty liver disease, AFLD). Clinical and histological studies suggest that NAFLD and AFLD share
pathogenic mechanisms. Nevertheless, current data are still inconclusive as to whether the underlying biological process
and disease pathways of NAFLD and AFLD are alike. Our primary aim was to integrate omics and physiological data to
answer the question of whether NAFLD and AFLD share molecular processes that lead to disease development. We also
explored the extent to which insulin resistance (IR) is a distinctive feature of NAFLD. To answer these questions, we used
systems biology approaches, such as gene enrichment analysis, protein–protein interaction networks, and gene
prioritization, based on multi-level data extracted by computational data mining. We observed that the leading disease
pathways associated with NAFLD did not significantly differ from those of AFLD. However, systems biology revealed the
importance of each molecular process behind each of the two diseases, and dissected distinctive molecular NAFLD and
AFLD-signatures. Comparative co-analysis of NAFLD and AFLD clarified the participation of NAFLD, but not AFLD, in
cardiovascular disease, and showed that insulin signaling is impaired in fatty liver regardless of the noxa, but the putative
regulatory mechanisms associated with NAFLD seem to encompass a complex network of genes and proteins, plausible of
epigenetic modifications. Gene prioritization showed a cancer-related functional map that suggests that the fatty
transformation of the liver tissue is regardless of the cause, an emerging mechanism of ubiquitous oncogenic activation. In
conclusion, similar underlying disease mechanisms lead to NAFLD and AFLD, but specific ones depict a particular disease
signature that has a different impact on the systemic context.
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Introduction
The abnormal accumulation of fat in the liver–or hepatic
steatosis–is often related either to metabolic risk factors associated
with metabolic syndrome (MetS) in the absence of alcohol
consumption (nonalcoholic fatty liver disease, NAFLD) or to
chronic alcohol consumption (alcoholic fatty liver disease, AFLD).
Despite the fact that the causative noxa for each clinical entity is
different, both the diseases share the same natural history; e.g., the
evolution of liver histology of NAFLD and AFLD varies from
simple steatosis to cirrhosis, including an increased risk of
hepatocellular carcinoma [1,2]. The clinical features are strength-
ened by the liver pathology as NAFLD and AFLD share a number
of histological changes, including the presence of lobular
inflammation, morphological changes in liver mitochondria,
perivenular and perisinusoidal fibrosis, and even hepatocellular
ballooning [3,4]. In fact, nonalcoholic steatohepatitis (NASH) was
initially regarded by Lugwig J et al. as a histological picture that
mimics alcoholic hepatitis [5].
Interestingly, advances in genome analysis have shown that
rs738409 C/G, a nonsynonymous coding (I148M) gene variant
located in human patatin-like phospholipase domain containing 3
gene (PNPLA3, also known as adiponutrin), is critically involved in
the genetic susceptibility of fatty liver in both NAFLD [6,7] and
AFLD [8]. Furthermore, rs738409 not only modulates the amount
of intrahepatic triglyceride content, but also the histological disease
severity, including necroinflammation and fibrosis in both NAFLD
[7,9] and AFLD [10,11].
In addition, it has also been suggested that NAFLD and AFLD
might have similar pathogenic mechanism because both are
associated with hepatic inflammatory changes and local upregula-
tion of cytokine production, along with increased fibrogenesis.
Nevertheless, there is still inconclusive data regarding whether the
underlying biological process and disease pathways of NAFLD and
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AFLD are identical; in fact, the differences between them have
been suggested [12]. Consequently, some critical questions remain
unanswered, such as whether insulin resistance (IR) is associated
with both NAFLD and AFLD, whether hepatic necroinflamma-
tion is related to similar triggering events, and whether cardio-
vascular disease is equally associated with both the liver disorders.
The omics revolution (genomics, proteomis, transcriptomics, and
metabolomics) has significantly changed our understanding about
the pathogenesis of complex diseases.
Nevertheless, the multi-level high-throughput omics data are
growing exponentially, sometimes negatively impacting our
capacity of extracting and interpreting biological insights from
them. Fortunately, interesting computational resources have been
developed, such as data-mining techniques, which not only help us
in assembling information from the biomedical literature, but are
also devoted to uncover details that are of practical value for
reveling disease pathogenesis.
Hence, our primary aim was to integrate genomic, molecular,
and physiological data about NAFLD and AFLD to answer the
question of whether both the diseases share the same underlying
pathogenic mechanisms. In addition, we explored the biological
processes and associated-disease pathways behind NAFLD and
AFLD to evaluate the extent to which IR is (or is not) a distinctive
feature between them.
To answer these questions, we used data mining and systems
biology approaches, such as a gene enrichment analysis and
protein–protein interaction networks.
Materials and Methods
Data collection and computational data mining
To assemble the available evidence about NAFLD- and AFLD-
associated biological processes in a systematic manner, we used the
text mining platform PESCADOR (Platform for Exploration of
Significant Concepts Associated to co-Occurrence Relationships)
[13]. This resource allows collecting information about NAFLD/
AFLD-related pathobiology to predict further biomolecular
interactions among genes and proteins associated with them.
PESCADOR selects gene/protein co-occurrence pairs based on
their relatedness to biological concepts, bringing together, under a
common perspective, protein interactions that have not been
studied under the same research focus [13].
Thus, with the queries ‘‘alcoholic AND (steatosis OR fatty liver)
NOT (non or nonalcoholic)’’ for AFLD and ‘‘nonalcoholic OR
non-alcoholic AND fatty liver OR steatosis’’ for NAFLD, we
retrieved 823 papers and 1345 co-occurrences for AFLD, and 868
papers and 2217 co-occurrences for NAFLD. The query involves
retrieving extensible markup language (XML) PubMed abstracts
for PMID list, passing XML PubMed abstracts for NLPROT
analysis (a tool for finding protein names in natural language text),
and tagging protein names and performing co-occurrences
analyses. After carrying out terms’ tagging, a total of 228 gene/
protein terms were identified for AFLD (Table S1) and 314 terms
were found for NAFLD (Table S2).
Of note, the data mining method implemented in PESCADOR
is based on the LAITOR (Literature Assistant for Identification of
Terms co-Occurrences and Relationships) tool [14] that ensures
the users the analysis of the meaning of the text, not just the
presence of key words. Actually, LAITOR identifies biointeraction
terms in the text of the abstracts according to a dictionary of
biointeraction terms [13,14]. In addition, other available platforms
are not flexible enough as PESCADOR to filter interactions
extracted from a PubMed query.
Systems biology approaches for gene enrichment
analysis and protein–protein interaction networks
Based on the list of genes/proteins identified as explained
earlier, we decided to explore the interactions between them in an
integrative fashion to provide a ‘‘functional molecular map’’ of
both the clinical disorders. Thus, functional enrichment analysis
was performed by the bioinformatic resource ToppGene Suite
(http://toppgene.cchmc.org) and ToppCluster (http://toppcluster.
cchmc.org), which could detect functional enrichment of the
candidate genes/proteins list based on Transcriptome, Proteome,
Regulome (TFBS and miRNA), Ontologies (gene ontology GO,
Pathway), Phenotype (human disease and mouse phenotype),
Pharmacome (Drug-Gene associations), literature co-citation, and
other features [15].
This application was selected because the gene functional
annotations are based on a comprehensive list of databases that
includes among others, annotation for drugs, disease and mouse
phenotype, miRNAs, and allows the identification and prioritiza-
tion of novel disease candidate genes in the interactome.
Furthermore, the statistical methods for quantitative enrichment
are reliable [16].
In addition, we used a strategy of gene prioritization under the
hypothesis that the already known associated disease loci and
proteins might be useful as a template to look for unknown
molecular targets involved in the pathogenesis of NAFLD and
AFLD. Thus, we performed a comprehensive analysis of candidate
regions generated by the freely accessible ENDEAVOUR software
available at http://homes.esat.kuleuven.be/˜bioiuser/endeavour/
endeavour.php.
ENDEAVOUR is a software application for the computational
prioritization of candidate genes underlying biological processes or
diseases, based on their similarity to known genes involved in a
disease as previously described [17]. The hypothesis of prioritiza-
tion by ENDEAVOUR is that candidate test genes are ranked
based on their similarity with a set of known training genes; this
strategy allows expansion of the selection of putative molecular
targets and prediction of new targets. Terms lists for NAFLD and
AFLD, shown in Table S1 and Table S2, were used as training
genes in the Endeavour platform; subsequently, the application
prioritized the entire human genome looking for similarities
between the candidates and the models built with the training
genes. This prioritization covers most of the aspects of knowledge
available on genes and gene products (functional annotations,
protein interactions, expression profiles, regulatory information,
sequence-based data, and literature mining) [18].
This application was selected because its system was validated
experimentally by extensive leave-one-out cross-validations show-
ing an excellent performance [18]. In addition, the platform
ENDEAVOUR allows users to prioritize candidate genes not only
with respect to their biological processes but also diseases of
interest. Furthermore, we have experimentally validated the
putative associations of variants of IGF1R with arterial hyperten-
sion and HNF4a with type 2 diabetes after being predicted by this
tool [19,20].
Figures were constructed under the graphical platforms for
exploring the biological networks, MEDUSA [21] or Cytoscape
v2.8 [22].
Results
The results of text mining for biomolecular interactions among
terms associated with AFLD and NAFLD are shown in Figures 1
and 2, respectively.
NAFLD and ALFD Common Pathways
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Once AFLD-associated terms and interactions were displayed
graphically, a dendriform hierarchical hub appeared centered on
CYP2E1, TNFa, CD14 (a surface antigen that is preferentially
expressed on monocytes/macrophages), IL10, PPARa, and the
apoptosis regulator BCLXL (Figure 1). On the contrary, once
NAFLD-associated terms were displayed graphically, a stepwise
hierarchical central hub appeared centered on the apoptosis-
mediating surface antigen FAS, the protein kinase AMP-activated
AMPK (an energy sensor protein kinase that plays a key role in
regulating cellular energy metabolism), insulin, and C-reactive
protein (Figure 2); in addition, two-side nodes centered on IL6
and CD36 were also displayed.
Furthermore, based on the candidate gene/protein lists
identified by the text-mining tool (Table S1 and Table S2),
we performed a functional enrichment analysis. Interestingly, the
analysis showed that AFLD-reported loci and proteins are
integrated into several similar functional pathways and biological
processes that did not significantly differ from those of NAFLD
(Table 1). For example, analysis of GO molecular function
showed that ‘‘receptor binding,’’ ‘‘cytokine receptor binding’’ and
‘‘lipid binding,’’ among other GO terms, were highly predicted for
both AFLD and NAFLD. In fact, there was an almost perfect
match between AFLD and NAFLD GO Molecular function
terms, except for GO term ‘‘monocarboxylic acid binding’’ that
was only predicted for AFLD (Table 1).
Functional analysis of the top 10 GO Biological Process showed
that AFLD was significantly associated with the modulation of
immune function because the highly significant terms were
GO:0002376 Immune system process, GO:0002682 Regulation
of immune system process, and GO:0006955 Immune response
(Table 1). In contrast, functional analysis of the top 10 GO
Biological Process showed that NAFLD was significantly associ-
ated with GO:0009725 Response to hormone stimulus,
GO:0009893 Positive regulation of metabolic process,
GO:0006629 Lipid metabolic process, and GO:0042981 Regula-
tion of apoptotic process.
Accordingly, AFLD was significantly associated with toll-like
receptor signaling and cytokine related pathways, while NAFLD
showed significant association with adipocytokine and apoptosis
signaling pathway (Table 1). It is worth mentioning that pathways
in cancer were highly predicted for both the diseases, and
keratinocyte differentiation was a distinctive pathway only
predicted for NAFLD.
Among the highly ranked gene families, CD (cluster of
differentiation) molecules as well as interleukins and interleukin
receptors were overrepresented in both AFLD and NAFLD, but
ATP-binding cassette transporters, caspases, and acyl-CoA syn-
thetases were only significantly predicted in NAFLD (Table 1).
Remarkably, predicted interactions among candidate terms for
AFLD showed mitogen-activated protein kinases as highly ranked.
Conversely, STAT3, IRS1, NCOR2 (a transcriptional co-repres-
sor of NR4A2/NURR1 that acts through histone deacetylases,
HDACs), and EP300 (E1A-binding protein p300 that functions as
HDAC regulating transcription via chromatin remodeling during
cell proliferation and differentiation) were significant for NAFLD
(Table 1), suggesting, as we recently reported, that epigenetic
factors play a critical role in the disease progression, not only
involving nuclear DNA [23], but mitochondrial DNA as well [24].
Figure 1. Graphic illustration of genes/proteins co-occurrence and their relatedness to biological concepts with the query
‘‘alcoholic AND (steatosis OR fatty liver) NOT (non or nonalcoholic)’’. Prediction was performed by PESCADOR (available at http://cbdm.
mdc-berlin.de/tools/pescador/), a web-based tool to assist large-scale integration text-mining of biointeractions extracted from MEDLINE abstracts.
The graph was constructed using the free available program MEDUSA, which is a Java application for visualizing and manipulating graphs of
interaction (www.bork.embl.de/medusa) [21,33].
doi:10.1371/journal.pone.0058895.g001
NAFLD and ALFD Common Pathways
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Prediction of relatedness with mouse phenotype showed that
candidate AFLD genes/proteins were significantly associated with
abnormal liver and hepatobiliary system morphology, and to a
lesser extent with lipid metabolism; on the other hand, candidate
NAFLD gene/ proteins were significantly associated with glucose
and lipid homeostasis (Table 1).
We further performed a multiple genes/ proteins analysis that
simultaneously encompassed the candidate list of AFLD and
NAFLD to obtain a functional modular map that identifies shared
and specific features of each disease, including potential regulatory
mechanism relationships. Figure 3 summarizes the disease
pathways shared by AFLD and NAFLD, and those that are
overrepresented specifically for each disease. Remarkably, apop-
tosis, IL6-mediated signaling, NF-k-b and JAK-STAT pathways,
metabolism of lipids and lipoproteins, and pathways in cancer
were placed in the overlapping zone and were shared between the
two data sets. Accordingly, interleukins (1A, 3, 4, 10, and 18),
adiponectin, PPARs (a and c), sirtuin 1, TNFa, STAT3, INSR,
SERBP1 or PAI-1, ICAM1, among the others, were also shared
between the two sets (Figure 3).
Cross-comparing enrichment analyses showed that NAFLD is
associated with a myriad of complex pathways that include among
the others, insulin signaling, caspases and mitochondrial-related
apoptosis, stress induction of heat shock proteins, cellular
proliferation, hypoxia induction, and protein associated with
epigenetic regulation (Figure 3).
Conversely, cross-comparing enrichment analyses showed that
AFLD is associated with a more reduced network of disease
pathways, mostly focused on modulation of the immune response,
toll-like receptor signaling, and cytokines (Figure 3).
Interestingly, cardiovascular-related pathways were more en-
riched in NAFLD in comparison with AFLD (platelet plug
formation and endothelins), as shown in Figure 3. Regarding
lipid metabolism, AFLD pathways were associated with glycer-
olipids and ceramid signaling, and NAFLD pathways were
associated with lipoprotein metabolism and chylomicron-mediated
lipoprotein transport (Figure 3). Details about clusters of
function-disease-related genes and proteins are given in Figure
S1, and a functional modular map of the multiple gene/ protein
analysis encompassing the candidate list of NAFLD and AFLD
based on cellular component is shown in Figure S2. Of note,
although there are specific genes associated with either AFLD or
NAFLD, there is not a specific pathway for both of the diseases.
Is alcohol associated with impaired insulin signaling and
IR?
Our secondary aim was to explore whether impaired insulin
signaling is a molecular process associated with both the
conditions, regardless of the insult (either metabolic or alcohol),
or if IR is restricted to NAFLD and thereby to MetS.
Comparative co-analysis of both the data sets showed that
insulin signaling is impaired in both the liver disorders, but the
biological processes and putative regulatory mechanisms associat-
ed with NAFLD seem to encompass a large interconnected
network of genes and proteins, including, but not restricted to,
FOXO1, SIRT1, dipeptidylpeptidase IV (DPP4, a cell surface
glycoprotein receptor involved in the co-stimulatory signal
essential for T-cell receptor-mediated T-cell activation and also
an enzyme involved in neuropeptides and incretins degradation,
i.e. NPY and GLP1), PPARc, PER, and HDAC3 (Figure 4). By
Figure 2. Graphic illustration of genes/proteins co-occurrence and their relatedness to biological concepts with the query
‘‘nonalcoholic OR non-alcoholic AND fatty liver OR steatosis’’. Prediction was performed by PESCADOR (available at http://cbdm.mdc-berlin.
de/tools/pescador/), a web-based tool to assist large-scale integration text-mining of biointeractions extracted from MEDLINE abstracts. The graph
was constructed using the free available program MEDUSA, which is a Java application for visualizing and manipulating graphs of interaction (www.
bork.embl.de/medusa) [21,33].
doi:10.1371/journal.pone.0058895.g002
NAFLD and ALFD Common Pathways
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the contrary, insulin signaling in AFLD is highly related to and
specifically focused on TNFa, PPARc, and TGBFb (Figure 4).
Gene prioritizations shows that fatty liver either associated with
metabolic factors or alcohol is strongly associated with cancer
pathways and ubiquitously malignant cellular transformation
We used the above-explained approach of gene prioritization,
and based on the results of ENDEAVOUR output, we selected the
top-ranked candidate genes prioritized for NAFLD (Table S3)
and AFLD (Table S4), based on the top-ranked significant P-
values that reflect the significance of enrichment. Then, we
performed a new comparative co-analysis of both the data sets
generated by ENDEAVOUR, and we explored novel putative
disease pathways. Surprisingly, in addition to genes associated with
IR or type 2 diabetes, i.e. HNF4A [20], the integrative functional
analysis of the shared pathways between NAFLD and AFLD
showed a significant enrichment of biological processes associated
with cancer and neoplastic transformation of other nonhepatic
tissues, such as colorectal, prostate, pancreas, bladder, renal,
endometrial, and thyroid cancer (Figure S3). Moreover, growth
factors associated signaling pathways involved in cell proliferation,
cell migration, survival, and chemotaxis, such as IGF, PDGF or
their receptors, and growth factors active in angiogenesis and
endothelial cell growth, such as VEGF, were also highly enriched
(Figure S3).
Diseases-related microRNAs and regulation of gene
transcription in AFLD and NAFLD
Integrative functional analysis showed novel microRNAs
(miRNAs) that might modulate AFLD, such as miR-9, or NALFD,
such as miR-146a, miR-18a, and miR-22 (Figure 5). Remark-
ably, miR-7a and miR-199a-3p were found to be placed in the
shared area of AFLD and NAFLD, and were predicted as related
to apoptosis and inflammation-related network integrated by IL6,
BCL2, caspase 3, NF-k-b, CD40L, MAPKs, and PTEN
(Figure 5). Again, it was noted that there is no specific miRNA
associated with a gene involved in any particular disease.
Comparative co-analysis of both the data sets generated by
ENDEAVOUR platform showed an even more complex predic-
tion of miRNA (Figure S4). Interestingly, based on these different
targets, some miRNAs, such as miR-7a and miR-146a, were once
again predicted.
Discussion
NAFLD and AFLD are both leading causes of non-viral chronic
liver diseases, and the prevalence of these two clinical disorders is
constantly growing worldwide.
There is agreement about the fact that the clinical distinction
between NAFLD and AFLD is often challenging, and misclassi-
fication owing to difficulties in collecting reliable information
Figure 3. Graphic illustration of a functional modular map of the multiple gene/ protein analysis encompassing the candidate list of
NAFLD and AFLD based on disease pathways. Results of functional association analysis performed by the bioinformatics resource ToppCluster
(http://toppcluster.cchmc.org) based on pathways networks showing enriched terms from Gene Ontology, Mouse Phenotype, Co-expression,
microRNAs, and transcription factors for the NAFLD- and AFLD-specific gene/protein lists. Right side of the figure depicts the highly significant
enrichments for sets of genes and proteins of the NAFLD term list; left side of the figure depicts the highly significant enrichments for sets of genes
and proteins of the AFLD term list; and the analysis of genes and intersection of pathways between NAFLD and AFLD is shown in the center part of
the figure. Terms in red represent genes/proteins, and terms in green represent disease pathways in GO terms. The graph was constructed using the
free available program Cytoscape, a software project for integrating biomolecular interaction networks with high-throughput expression data and
other molecular states into a unified conceptual framework [22].
doi:10.1371/journal.pone.0058895.g003
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about the amount of alcohol consumption from patients is a source
of bias. Likewise, the pathogenic distinction between both the
disorders is not only fuzzy, but physicians agree that similar major
molecular mechanisms are shared between NAFLD and AFLD,
including inflammatory pathways and fibrogenesis [12,25].
Nevertheless, the evidence is still questionable because the disease
Figure 4. Comparative co-analysis of NAFLD and AFLD data sets focused on insulin signaling. Results of functional association analysis
performed by the bioinformatics resource PESCADOR (available at http://cbdm.mdc-berlin.de/tools/pescador/), a web-based tool to assist large-scale
integration text-mining of biointeractions extracted from MEDLINE abstracts with a focus in the selected terms. The graph was constructed using the
free available program, MEDUSA, which is a Java application for visualizing and manipulating graphs of interaction (www.bork.embl.de/medusa)
[21,33]. The thickness of the green lines signifies greater significance.
doi:10.1371/journal.pone.0058895.g004
Figure 5. Functional enrichment analysis of putative miRNAs associated with NAFLD and AFLD. The network is shown as a cytoscape
graph [22] generated from ToppCluster (available at toppcluster.cchmc.org/) network analysis.
doi:10.1371/journal.pone.0058895.g005
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pathways and molecular process are often explored individually,
instead of working in concert, and these liver disorders are seldom
treated as what they truly are: complex diseases. In this study, we
proposed an exploration about the disease pathways associated
with NAFLD and AFLD based on systems biology under the
hypothesis that a more integrative analysis of the pathogenesis of
these diseases may have a strong impact not only on their clinical
and molecular knowledge, but also on the interventional programs
and putative emerging therapies. In that sense, our analysis
showed that vitamins (vitamin A, C, D, and E), natural substances
(resveratrol, genistein, hormones), or drugs (metformin, statins,
indomethacin) may have beneficial effects on fatty liver, indepen-
dently of the causative noxa (Figure S5).
What this study tells us about the pathogenesis of
NAFLD and AFLD?
Our primary result basically showed that the leading biological
process and disease pathways associated with NAFLD did not
significantly differ from those predicted for AFLD. Nevertheless,
systems biology revealed the weight of each molecular process
behind each of the two diseases, and dissected distinctive
molecular NAFLD and AFLD signatures.
For instance, apoptosis seems to be the common cell death
process in NAFLD and AFLD, but AFLD is mainly associated
with the so-called extrinsic pathway related to tumor necrosis
family, which would be modulated by proapoptotic BCl2 family
members. In contrast, NAFLD seems to be primary associated
with FAS-induced apoptosis, which is highly interconnected to an
intricate network of metabolic stressors, activation of caspases, and
a collection of proteins that modulate apoptosis, necrosis, and
inflammation. It is worth mentioning that changes in mitochon-
drial membrane permeabilization and endoplasmic reticulum
stress are central features in both AFLD and NAFLD, as shown in
the prediction of the cellular compartment (Figure S2).
Moreover, integration of the biological process and disease
pathways associated with NAFLD showed that the fatty liver of the
MetS reprograms the body lipid and glucose metabolism, and
these events might be mediated, among the others, by hypoxia and
epigenetic changes. The latter observation is in agreement with
previous novel findings of our group, which demonstrated that
DNA methylation of gene promoters in the liver tissue is critically
involved in the modulation of peripheral IR [23], and epigenetic
changes in mitochondrial DNA mediates NAFLD disease
progression [24]. Furthermore, the integrative analysis focused
on interactions among terms significantly predicted histone
acetyltransferase p300 (EP300), which is a co-activator of
hypoxia-inducible factor 1a and is an acetyltransferase for histone
and nonhistone targets, all of which are highly involved in the
endogenous circadian clock pathway. It is noteworthy that CLOCK
variants were reported to be associated with NAFLD [26].
NAFLD was also found to be associated with keratinocyte
differentiation pathway, which suggests the involvement of MAPK
pathway in the disease biology; this finding is plausible with the
molecular cascades involved in apoptosis, inflammation, cell
growth, and differentiation observed in this disease.
Conversely, integration of the biological process and disease
pathways associated with AFLD showed that the insult triggers a
strong local immune response that is associated with the release of
a plethora of cytokines. Thereby, all further metabolic changes in
the liver tissue are downstream events of the local and powerful
immune response.
Some comments about the limitations of this study may be
added. For example, despite the fact that NAFLD and AFLD are
processes that have been studied for decades, some unpublished
aspects yet to be uncovered were not included in data mining.
Hence, the results of this study only integrate the published
knowledge about both the diseases. Nevertheless, although the
functional exploration and enrichment analysis have largely
expanded the pre-existing knowledge, the term list of each disease
has the limitations of any method that relies on literature analysis.
What this study tells us about the impact of NAFLD and
AFLD on the risk of systemic diseases?
Functional enrichment analysis showed interesting areas of
putative future research, such as the role of the predicted
miRNAs–let-7a, miR-146a, and miR-199a–in the pathogenesis
of both the diseases. Remarkably, miR-199a has been recently
found to be involved in myocardial infarction and other cardiac
diseases [27], and miRNA-let-7a has been noted to be involved in
epigenetics-miRNA regulatory pathways [28]. These findings
remain unexplored and deserve follow-up and exploration in
human studies, particularly because we do believe that miRNAs
may constitute a novel endocrine system [24].
Although there are numerous studies showing molecular
mechanisms associated with NAFLD and AFLD, they have not
explained how molecular mediators interact with each other and
how these interactions perturb the systemic homeostasis. In this
study, we showed that both NAFLD and AFLD are strongly
associated with cancer-related pathways that do not seem to be
restricted to the liver. Surprisingly, comparative co-analysis of
NAFLD- and AFLD- related biological terms showed a cancer-
related functional map that suggests that the fatty transformation
of liver tissue, regardless of the insult, is an emerging mechanism of
oncogenic activation. These findings are supported by previous
clinical observations [29–31]. Moreover, our data may explain
previous reports about NAFLD patients predisposed to hepato-
cellular carcinoma in the absence of cirrhosis [32]. It would be
interesting to answer this question in clinical studies that explore
for instance, patterns of gene expression in hepatocellular
carcinoma and surrounding nonneoplastic liver tissue in noncir-
rhotic patients with NAFLD and AFLD.
Finally, two remarkable findings were emphasized by this study.
First, systems biology shed light on the participation of NAFLD,
but not AFLD, in cardiovascular disease, because the integrative
analysis highlighted the role of NAFLD in thrombotic events and
modulation of vasculature behavior by the release of endothelins.
Second, NAFLD and AFLD were found to be associated with
impairment of insulin signaling and IR; while NAFLD-linked IR
was noted to be a multifaceted process that involves several
molecular processes working in concert; on the other hand,
AFLD-linked IR was observed to be rather the consequence of
TNFa-related signaling and subsequent local modulation of the
insulin receptor-activated pathways.
In conclusion, over the past 40 years many advances have been
made in our understanding of fatty liver and the mechanisms by
which it develops. New evidence from the clinical classification of
NAFLD and AFLD suggests that there are shared mechanisms
between them. Hence, taken together, these data suggest that
similar disease mechanisms lead to the clinical outcome of NAFLD
and AFLD, but specific ones depict a particular signature that
correlates to the impact of each phenotype in the systemic context.
The molecular understanding of the shared and specific mecha-
nisms will improve our knowledge of how fatty liver and disease
progression occur, eventually leading to the development of
improved noninvasive diagnostic tools and novel therapeutic
agents.
For instance, the analysis of putative drugs associated with the
explored disease pathways might suggest that some natural
NAFLD and ALFD Common Pathways
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substances, like resveratrol, or some drugs like metformin, losartan
or statins, might be equally beneficial to improve fatty liver,
independently of the causative noxa. On the other hand, in order
to envision non invasive diagnostic tools for monitoring the disease
severity, one might speculate that pathways associated with TNFa-
mediated immune response might be useful for AFLD and
pathways associated with FAS-induced apoptosis and caspases
activation might be effective for NAFLD.
Likewise, this knowledge would help to relax our restrictions on
NAFLD/AFLD disease classification based specifically on the
amount of alcohol consumption when limits are not toxic
quantities, but barely exceed the NAFLD classification limits
(,60–120 g/day of alcohol).
Implications and future directions
An integrative knowledge about the disease pathogenesis of
NAFLD and ALFD will pave the way towards formulation of new
hypothesis. In addition, if underlying mechanisms are common,
the same future therapeutic approaches may improve both
conditions. Nevertheless, more experimental data and clinical
studies are needed in order to accomplish this observation.
Supporting Information
Figure S1 Graphic illustration of a functional modular map
of the multiple gene/ protein analysis encompassing the
candidate list of NAFLD and AFLD based on functional
genes. Results of functional association analysis performed by the
bioinformatics resource ToppCluster (http://toppcluster.cchmc.org).
Right side of the figure depicts the highly significant enrichments
for sets of genes (red hexagon) of the NAFLD term list; left side of
the figure depicts the highly significant enrichments for sets of
genes of the AFLD term list; and the analysis of the intersection of
genes and gene functions (green squares) between NAFLD and
AFLD is shown in the center of the figure. The network is shown
as a cytoscape graph.
(TIF)
Figure S2 Graphic illustration of a functional modular map
of the multiple gene/ protein analysis encompassing the
candidate list of NAFLD and AFLD based on cellular
component. Results of functional association analysis performed
by the bioinformatics resource ToppCluster (http://toppcluster.
cchmc.org). Right side of the figure depicts the highly significant
enrichments for cellular components (green squares) of the
NAFLD-term list; left side of the figure depicts the highly
significant enrichments for cellular components of the AFLD term
list; and the genes (red hexagons) and analysis of the intersection
between NAFLD and AFLD is shown in the center of the figure.
The network is shown as a cytoscape graph.
(TIF)
Figure S3 Computational prioritization of candidate
genes underlying NAFLD and AFLD and comparative co-
analysis of genes pathways (green squares). Prioritization
was done by the bioinformatic tool ENDEAVOUR, and the figure
shows the results of the cluster analysis of the first top 200
prioritized candidate genes from the whole human genome
(23.712 genes), with a significant association with the training set
of NAFLD and AFLD. Functional association analysis was
performed by the bioinformatics resource ToppCluster (http://
toppcluster.cchmc.org). Right side of the figure depicts the highly
significant enrichments for sets of genes (red hexagons) of the
NAFLD term list; left side of the figure depicts the highly
significant enrichments for sets of genes of the AFLD term list; and
the analysis of the intersection of functional genes between
NAFLD and AFLD is shown in the center of the figure. The
network is shown as a cytoscape graph.
(TIF)
Figure S4 Computational prioritization of candidate
genes underlying NAFLD and AFLD and comparative co-
analysis of predicted miRNAs (violet squares). Prioritiza-
tion was done by the bioinformatic tool ENDEAVOUR, and the
figure shows the results of the cluster analysis of the first top 200
prioritized candidate genes (red squares) from the whole human
genome (23.712 genes), with a significant association with the
training set of NAFLD and AFLD. Functional association analysis
was performed by the bioinformatics resource ToppCluster (http://
toppcluster.cchmc.org). The network is shown as a cytoscape
graph.
(TIF)
Figure S5 Computational prioritization of candidate
genes underlying NAFLD and AFLD and comparative co-
analysis of predicted drugs (orange squares). Prioritiza-
tion was done by the bioinformatic tool ENDEAVOUR, and the
figure shows the results of the cluster analysis of the first top 200
prioritized candidate genes (red squares) from the whole human
genome (23.712 genes), with a significant association with the
training set of NAFLD and AFLD. Functional association analysis
was performed by the bioinformatics resource ToppCluster (http://
toppcluster.cchmc.org). The network is shown as a cytoscape
graph.
(TIF)
Table S1 Genes terms identified in 823 published
abstracts by the PESCADOR platform (Platform for
Exploration of Significant Concepts Associated to co-
Occurrence Relationships) with the query ‘‘alcoholic
AND (steatosis OR fatty liver) NOT (non or nonalcohol-
ic)’’ for AFLD.
(DOC)
Table S2 Genes terms identified in 868 published
abstracts by the PESCADOR platform (Platform for
Exploration of Significant Concepts Associated to co-
Occurrence Relationships) with the query ‘‘nonalcoholic
OR non-alcoholic) AND (fatty liver OR steatosis)’’ for
NAFLD.
(DOC)
Table S3 Results of gene prioritization: the top ranked
candidate genes prioritized for NAFLD.
(DOC)
Table S4 Results of gene prioritization: the top ranked
candidate genes prioritized for AFLD.
(DOC)
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